GlitchGoblin
Well-known member
New Breakthrough in Sight Restoration: Tiny Implant Brings Reading Back to Some Legally Blind Patients
A groundbreaking study has revealed that a tiny implant combined with special glasses can help some legally blind patients regain their ability to read. The treatment, known as the Photovoltaic Retina Implant Microarray (PRIMA), involves inserting a minuscule implant thinner than human hair under the retina and wearing special glasses with a video camera that projects what it sees via near-infrared light to the implant.
In a clinical study of 32 patients with geographic atrophy, an advanced form of dry age-related macular degeneration affecting five million people worldwide, 26 showed significant improvement in visual acuity after just one year. The treatment has been hailed as a major breakthrough by experts, offering hope for patients who have lost their central vision.
One patient, 70-year-old Sheila Irvine, described her experience with the PRIMA glasses as "out of this world," saying it was wonderful to be able to read and do crosswords again. However, she noted that the treatment still requires a lot of concentration and can focus on only a few letters at a time.
The treatment is the first to specifically target patients with geographic atrophy who have lost their central vision. Until recently, there had been no effective treatment to improve reading abilities or recognize faces. The FDA has approved Syfovre, a drug that slows down disease progression but does not reverse it, and the PRIMA implant marks a significant shift in treatment options.
Dr. Frank Holz, lead author of the study, noted that this device restores visual acuity in patients who have lost their central vision, making it an exciting development for those affected by geographic atrophy. However, Dr. Jon LaPook cautioned that the clinical study is small and the PRIMA implant is not yet licensed or available as a treatment outside of trials.
The Science Corporation has stated that they are committed to pioneering technologies that provide hope to patients in need and have expressed excitement about the potential of PRIMA to redefine vision restoration for those affected by geographic atrophy. While there is still much to be learned, this breakthrough offers new possibilities for those living with age-related macular degeneration.
A groundbreaking study has revealed that a tiny implant combined with special glasses can help some legally blind patients regain their ability to read. The treatment, known as the Photovoltaic Retina Implant Microarray (PRIMA), involves inserting a minuscule implant thinner than human hair under the retina and wearing special glasses with a video camera that projects what it sees via near-infrared light to the implant.
In a clinical study of 32 patients with geographic atrophy, an advanced form of dry age-related macular degeneration affecting five million people worldwide, 26 showed significant improvement in visual acuity after just one year. The treatment has been hailed as a major breakthrough by experts, offering hope for patients who have lost their central vision.
One patient, 70-year-old Sheila Irvine, described her experience with the PRIMA glasses as "out of this world," saying it was wonderful to be able to read and do crosswords again. However, she noted that the treatment still requires a lot of concentration and can focus on only a few letters at a time.
The treatment is the first to specifically target patients with geographic atrophy who have lost their central vision. Until recently, there had been no effective treatment to improve reading abilities or recognize faces. The FDA has approved Syfovre, a drug that slows down disease progression but does not reverse it, and the PRIMA implant marks a significant shift in treatment options.
Dr. Frank Holz, lead author of the study, noted that this device restores visual acuity in patients who have lost their central vision, making it an exciting development for those affected by geographic atrophy. However, Dr. Jon LaPook cautioned that the clinical study is small and the PRIMA implant is not yet licensed or available as a treatment outside of trials.
The Science Corporation has stated that they are committed to pioneering technologies that provide hope to patients in need and have expressed excitement about the potential of PRIMA to redefine vision restoration for those affected by geographic atrophy. While there is still much to be learned, this breakthrough offers new possibilities for those living with age-related macular degeneration.